The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group

Paul A. Volberding, Stephen W. Lagakos, Janet M. Grimes, Daniel S. Stein, Henry H. Balfour, Richard C. Reichman, John A. Bartlett, Martin S. Hirsch, John P. Phair, Ronald T. Mitsuyasu, Margaret A. Fischl, Ruy Soeiro

Research output: Contribution to journalArticle

121 Scopus citations
Original languageEnglish (US)
Pages (from-to)437-442
Number of pages6
JournalJAMA: The Journal of the American Medical Association
Volume272
Issue number6
DOIs
StatePublished - Aug 10 1994

Cite this

Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H., Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., & Soeiro, R. (1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA: The Journal of the American Medical Association, 272(6), 437-442. https://doi.org/10.1001/jama.1994.03520060037029